Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients.

ABSTRACT: Lung cancer continues to be a major worldwide health issue, with more than 50% of patients having incurable metastatic disease at diagnosis. Fortunately, the advanced lung cancer treatment landscape is changing rapidly as a result of the positive impact of effective inhibitors of tumor driver mutations, and the more recent discovery that immune modulation with anti-PD-1/PD-L1 monoclonal antibodies results in tumor regression and prolonged survival. While a relatively small subset of lung cancer patients are candidates for inhibitors of driver mutations, the majority of advanced lung cancer patients are candidates for an immunotherapy regimen. Many of these patients have cachexia, which is associated with increased cancer therapy toxicity and possibly reduced responsiveness to immunotherapy

SUBMITTER: Bonomi P 

PROVIDER: S-EPMC6893632 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature